News - Today and tomorrow (Oct. 2 - 3), the main stakeholders of the pharmaceutical and biopharmaceutical industry, venture capital companies, academic researchers and government representative will be brought together for the 19th edition of BioContact Quebec. During two days, they will have the opportunity to develop new partnerships. "This is an exceptional opportunity for the pharmaceutical and biopharmaceutical industry, which has been experiencing major changes in the recent years", explained Dr. Martin Godbout, president of the event.
News - Aeterna Zentaris announces the successful completion of its previously announced agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide® product. The principal outcome of such agreements is the transfer of manufacturing rights and the grant of a manufacturing license for Cetrotide® to a subsidiary of Merck KGaA of Darmstadt, Germany, in all jurisdictions. Under the terms of these agreements, Aeterna Zentaris will receive a one-time payment of €2.5 million, or approximately $3.3 million. Cetrotide® (cetrorelix acetate for injection) is used to regulate hormone responses in women undergoing infertility treatment. Merck Serono currently markets Cetrotide®worldwide.
News - (Press release in french only) The first work meeting of Alliance santé Québec (Québec City Health Alliance) took place on October 1st, at Domaine Cataraqui in Qubec City. This new entity brings together key players from the greater Quebec City region working in in research and innovation in various health-related fields. Acting as as a forum for discussion and action, the group’s primary objective is to increase and optimize research efforts for the health of individuals and populations.
News - The 19th edition of BioContact Quebec, the international symposium on bio-pharmaceutical partnerships, will take place on October 2nd and 3rd. For two days, representatives of almost 100 pharmaceutical and bio-pharmaceutical companies from Canada, the United States and Europe as well as some 150 participants from universities, consulting firms, venture capital companies and government representatives will be on site to exchange and develop business partnerships.
News - Mitsubishi Tanabe Pharma Corporation and Medicago announced the completion of the previously announced acquisition of Medicago Inc. by MTPC. On September 18, 2013, 9284-9686 Québec Inc.,a subsidiary of MTPC, acquired all of the outstanding common shares of Medicago, other than the common shares currently held by MTPC and Philip Morris Investments B.V. an affiliate of Philip Morris International Inc., pursuant to the terms of an arrangement agreement made as of July 12, 2013. As a result, Medicago has become jointly owned by MTPC (60%) and PMI (40%).
News - As part of its mandate to support Canadian entrepreneurs, BDC Venture Capital announced today it has allocated $135 million in new capital to direct venture investments in innovative healthcare companies. That brings its total direct commitment to the sector to $270 million. Recognizing a massive and growing market opportunity, the BDC Venture Capital Healthcare Fund will broaden its investment strategy and invest in technology, products and services that aim to dramatically improve global healthcare productivity, efficiency and patient outcomes.
News - Héma-Québec, Québec City and the Government of Québec announce the construction of the C∙LAVIE complex, a cell production facility representing an investment of $21.5Mthat will be built in the Michelet innovation space within the territory of Québec City. The new building, with an area of 3,716 square metres, will provide a controlled environment (white rooms) that complies with good manufacturing practises (GMP), a pre-requisite for regulatory product approval. For the first few years, it will primarily be used to manufacture standardized cell and tissue products for clinical studies. Eventually, it will also ensure large-scale production of approved cellular medications.
News - Medicago is pleased to announce that the Superior Court of Quebec has granted its final order approving the previously announced plan of arrangement involving the Company, Mitsubishi Tanabe Pharma Corporation (MTPC) and 9284-9686 Québec Inc., a wholly-owned subsidiary of MTPC.
News - Nordic Life Science Pipeline launches a campaign to recruit 50 research subjects for the first clinical trials of SPINALONTM , an innovative oral tri-therapy aimed to trigger short episodes of rhythmic leg movements in severely spinal cord-injured subjects. Preclinical data strongly suggest that SpinalonTM is ideally suited to become a first-in-class therapy for spinal locomotor network activation, basic stepping movement generation and treadmill training in chronic, motor-complete, paraplegic and tetraplegic individuals classified as ASIA-A or ASIA-B. In 2009, the company signed an in-licensing agreement with UNIVERSITÉ LAVAL for the exclusive rights of developing Spinalon.
News - Aeterna Zentaris announces that the Company's President and CEO, David Dodd, will be presenting a corporate overview at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 9, 2013, at 10:50 am (Eastern), in Room 7.02 of the Millennium Broadway Hotel, in New York.